In contrast, reduced levels of the activation marker H3K4me3 were detected at both the MEOX2 (p≤0.028) and TWIST1 (p≤0.0006) promoter sequences in the high survival group of patients (Figure 4E–F) and were correlated with partial response to adjuvant cisplatinum or carboplatinum, as the first line chemotherapy in NSCLC patients (Table 1). Here, TWIST1 is linked to non-small cell lung carcinoma.